GlassScriptPhysician profile
Marialena Bucca
NPI 1578530168
$1,060.57
in general payments reported to CMS, 2019-2025
12 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $97.21 · 2022: $173 · 2023: $237 · 2024: $173 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $252.53 | 2019-2025 | |
| Sanofi Pasteur INC. | $204.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $181.81 | 2020-2025 | Vaxneuvance, Gardasil 9, Proquad |
| Kaleo, INC. | $105.89 | 2022-2024 | Auvi-Q |
| Genentech USA, INC. | $52.59 | 2019-2020 | |
| Organon LLC | $52.37 | 2025 | |
| Alk-Abello, INC | $48.86 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $47.14 | 2023 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $40.38 | 2024 | Ycanth |
| Cumberland Pharmaceuticals, INC. | $27.71 | 2024 | Kristalose |
| Sobi, INC | $23.93 | 2023 | |
| Glaxosmithkline, LLC. | $23.20 | 2023 | Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marialena Bucca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.